Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
about
Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roadsSpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesGold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial-mesenchymal transition inhibition.Meta-Analysis of Tumor Stem-Like Breast Cancer Cells Using Gene Set and Network Analysis.An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis.Identification of TAX2 peptide as a new unpredicted anti-cancer agent.The Role of EMT in Pancreatic Cancer ProgressionTissue transglutaminase: a new target to reverse cancer drug resistanceBIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based ChemotherapyAngiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancerA proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinomaControlling escape from angiogenesis inhibitors.NF-κB as a target for pancreatic cancer therapy.Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.Molecular targets on the horizon for kidney and urothelial cancer.Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma.Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.EMT and Treatment Resistance in Pancreatic Cancer.Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapyThe Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma.Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance.Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody.Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition
P2860
Q26830075-25C96E0D-4CEF-4DD5-860F-BBF02F336B7AQ26853171-CCDCFEDD-EA50-4BEB-B68F-915822BC58DEQ26991991-86B361BE-0670-4168-B73F-C9CC40EC4770Q27014174-0655C04E-C9A6-4786-BA26-3AC69AC6E47EQ33650400-26D2F217-CEEF-4408-9903-64CED7CD8686Q35921899-78B2A60B-B153-404F-B8C5-03594BB44FACQ35955457-7E1D3766-86FA-4BBC-90E2-86E6253EADE8Q36228487-034D1315-BF87-4BA0-A8F4-EE6515882CACQ36379750-D1AFC7DD-AF68-4836-82EB-7F3D13348F47Q36503511-16B40B82-432E-466E-A3A0-750612AD2FFEQ36927086-C44876DD-C865-4BD7-9175-3025441B0611Q36971532-FC6EDACB-BC41-48B5-9175-F6B5ED7CDFB0Q37081930-9257F12D-D930-4FA8-8C61-3110FF144015Q37640001-C719CAF5-9BA4-4BF5-9AAE-9BCA44B643EAQ37672654-5B5D6BBD-D55C-4F57-8F6F-D89C9B5D1444Q37996435-998ABF5C-468C-4BA8-AD85-741EA747C746Q38103859-2CD9ED79-20F9-4E99-B1BC-AFBAFD1EC0DFQ38132039-D375A948-38F6-4703-8036-634EBABEBD3CQ39042485-DF348C45-F31B-462F-96FD-C49FD50B7BD9Q39212474-A8833A65-0C1B-4BFD-A509-F3AD8A2D63ACQ41134105-8DA40807-AB4D-43D0-9308-3CAD5BA901ACQ41670877-C2D273C0-9D1E-4CFC-8E73-E974D1691FF8Q41809732-7F9B5E5F-D7BE-4A19-8F8F-0CB2E0235A37Q44456046-E41A0F50-4EAF-4F97-8867-45CF3F00127CQ45205085-AD224205-2563-459B-B3B4-D18A00D3BC1BQ47098476-D46B611E-5CE3-431E-BDF7-FF1CD2DCF184Q47699400-A380C46E-361F-45ED-8BAD-51943F51197FQ47777542-AD1BF8D0-5FCF-4AD0-B00F-4D3E97283C38Q52579594-F1F84E58-A5D5-4547-8055-F4358D24EBF2Q56942104-93DDE09C-A49A-4C61-944B-AE352A531F65
P2860
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anti-VEGF treatment-resistant ...... nducing an EMT cell phenotype.
@ast
Anti-VEGF treatment-resistant ...... nducing an EMT cell phenotype.
@en
type
label
Anti-VEGF treatment-resistant ...... nducing an EMT cell phenotype.
@ast
Anti-VEGF treatment-resistant ...... nducing an EMT cell phenotype.
@en
prefLabel
Anti-VEGF treatment-resistant ...... nducing an EMT cell phenotype.
@ast
Anti-VEGF treatment-resistant ...... nducing an EMT cell phenotype.
@en
P2093
P2860
P50
P1476
Anti-VEGF treatment-resistant ...... inducing an EMT cell phenotype
@en
P2093
Genni Paradiso
James L Abbruzzese
Paul J Chiao
P2860
P304
P356
10.1158/1078-0432.CCR-11-1185
P407
P577
2011-07-07T00:00:00Z